Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

NCT06002828 · tracked via the Priya Life Science Israel tracker

Sponsor

ECOG-ACRIN Cancer Research Group

Phase

Observational

Started

2023-10-13

Last updated

2026-09-15

Condition(s) studied

Acute Lymphoblastic LeukemiaHodgkin LymphomaNon-Hodgkin Lymphoma

Investigational drug(s) / intervention(s)

Non-Interventional Study

Non-Interventional Study: Non-interventional study

Study summary

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma or leukemia. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma or leukemia may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patient must be \>= 18 years of age at the time of registration * Patient must have been between the ages of 15-39 at the time of their first primary cancer diagnosis of Hodgkin lymphoma or non-Hodgkin lymphoma (NHL) or leukemia (acute lymphoblastic leukemia \[ALL\] only) * Patient must have completed therapy (with a complete response, per clinician determination) at the time of registration * Patients last date of prior systemic therapy for first primary diagnosis for Hodgkin lymphoma or non-Hodgkin lymphoma or leukemia (ALL) must have been within 3 years prior to registration * NOTE: Systemic therapy refers to all anti-cancer therapy, including but not limited to chemotherapy, intravenous (IV) or oral targeted medications, or radiation, and administered via a clinical trial or standard approach * Patient must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-3 * Patient must be English speaking in order to be able to complete the required QOL forms on this study * NOTE: Sites cannot translate the associated QOL forms * Patient must not be receiving active therapy for Hodgkin lymphoma or non-Hodgkin lymphoma or leukemia * Patient must have internet access through computer, tablet, or smartphone * Patient must have email address * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible

Primary outcome measure(s)

Impact of social-environmental risk factors on changes in Charlson Comorbidity Index (CCI) — Through Study Completion, up to 2 years.
Will fit Conway-Maxwell-Poisson mixed effects models with a log link to evaluate the impact of social-environmental risk factors on changes in CCI over time. Estimates will be reported as rate ratios (and 95% confidence intervals) on the link scale, with model-based marginal means by visit to aid interpretation on the count scale. Models will be fit by maximum likelihood using all observed visits; targeted diagnostics will assess dispersion, fit, and influence.

Trial sites (507)

Facility	City	Region
Anchorage Associates in Radiation Medicine	Anchorage	Alaska
Anchorage Radiation Therapy Center	Anchorage	Alaska
Alaska Breast Care and Surgery LLC	Anchorage	Alaska
Alaska Oncology and Hematology LLC	Anchorage	Alaska
Alaska Women's Cancer Care	Anchorage	Alaska
Anchorage Oncology Centre	Anchorage	Alaska
Katmai Oncology Group	Anchorage	Alaska
Providence Alaska Medical Center	Anchorage	Alaska
Fairbanks Memorial Hospital	Fairbanks	Alaska
Kingman Regional Medical Center	Kingman	Arizona
Mercy Hospital Fort Smith	Fort Smith	Arkansas
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro	Jonesboro	Arkansas
CARTI Cancer Center	Little Rock	Arkansas
PCR Oncology	Arroyo Grande	California
Providence Saint Joseph Medical Center/Disney Family Cancer Center	Burbank	California
Epic Care-Dublin	Dublin	California
Bay Area Breast Surgeons Inc	Emeryville	California
Epic Care Partners in Cancer Care	Emeryville	California
Contra Costa Regional Medical Center	Martinez	California
Providence Queen of The Valley	Napa	California
Bay Area Tumor Institute	Oakland	California
Stanford Cancer Institute Palo Alto	Palo Alto	California
Providence Medical Foundation - Santa Rosa	Santa Rosa	California
Providence Santa Rosa Memorial Hospital	Santa Rosa	California
Epic Care Cyberknife Center	Walnut Creek	California
BASS Medical Group - Lennon	Walnut Creek	California
Rocky Mountain Cancer Centers-Aurora	Aurora	Colorado
Boulder Community Foothills Hospital	Boulder	Colorado
Rocky Mountain Cancer Centers-Boulder	Boulder	Colorado
Rocky Mountain Cancer Centers - Centennial	Centennial	Colorado
The Women's Imaging Center	Denver	Colorado
Colorado Blood Cancer Institute	Denver	Colorado
Presbyterian - Saint Lukes Medical Center - Health One	Denver	Colorado
Rocky Mountain Cancer Centers-Midtown	Denver	Colorado
Rocky Mountain Cancer Centers-Rose	Denver	Colorado
Rose Medical Center	Denver	Colorado
Mountain Blue Cancer Care Center - Swedish	Englewood	Colorado
Rocky Mountain Cancer Centers - Swedish	Englewood	Colorado
Swedish Medical Center	Englewood	Colorado
The Melanoma and Skin Cancer Institute	Englewood	Colorado

+ 467 more sites — see the full list on the official registry below.

More ECOG-ACRIN Cancer Research Group trials in Israel

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Active, not recruiting

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Active, not recruiting

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Active, not recruiting

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer Active, not recruiting

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study Active, not recruiting

Other trials for the same condition

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Active, not recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Active, not recruiting

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Recruiting

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab Active, not recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06002828 on ClinicalTrials.gov ↗ ← All trials in Israel